MX2019005342A - Tratamiento de enfermedades del sistema nervioso central (snc) con estimulantes de guanilato ciclas solubles (sgc). - Google Patents

Tratamiento de enfermedades del sistema nervioso central (snc) con estimulantes de guanilato ciclas solubles (sgc).

Info

Publication number
MX2019005342A
MX2019005342A MX2019005342A MX2019005342A MX2019005342A MX 2019005342 A MX2019005342 A MX 2019005342A MX 2019005342 A MX2019005342 A MX 2019005342A MX 2019005342 A MX2019005342 A MX 2019005342A MX 2019005342 A MX2019005342 A MX 2019005342A
Authority
MX
Mexico
Prior art keywords
treatment
cns diseases
sgc
increase
sgc stimulators
Prior art date
Application number
MX2019005342A
Other languages
English (en)
Inventor
Wai-Ho Lee Thomas
Robert Perl Nicholas
Jung Joon
R Iyengar Rajesh
Germano Peter
Tang Kim
D Ribadeneira Maria
Original Assignee
Cyclerion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclerion Therapeutics Inc filed Critical Cyclerion Therapeutics Inc
Publication of MX2019005342A publication Critical patent/MX2019005342A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Uso de estimulantes de la guanilato ciclasa soluble (sGC), sales farmacéuticamente aceptables de los mismos y formulaciones farmacéuticas o formas de dosificación que comprenden a los mismos, ya sea solos o en combinación con uno o más agentes adicionales, para el tratamiento de varias enfermedades del SNC, en donde sería deseable un aumento de la estimulación de la sGC, o un aumento en la concentración de óxido nítrico (NO) o de guanosina 3´,5´-monofosfato cíclico (GMPc) o de ambos, o un aumento de la expresión de la vía del NO.
MX2019005342A 2016-11-08 2017-11-07 Tratamiento de enfermedades del sistema nervioso central (snc) con estimulantes de guanilato ciclas solubles (sgc). MX2019005342A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662419059P 2016-11-08 2016-11-08
PCT/US2017/060299 WO2018089328A1 (en) 2016-11-08 2017-11-07 Treatment of cns diseases with sgc stimulators

Publications (1)

Publication Number Publication Date
MX2019005342A true MX2019005342A (es) 2019-10-02

Family

ID=60452769

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019005342A MX2019005342A (es) 2016-11-08 2017-11-07 Tratamiento de enfermedades del sistema nervioso central (snc) con estimulantes de guanilato ciclas solubles (sgc).
MX2022010852A MX2022010852A (es) 2016-11-08 2019-05-07 Tratamiento de enfermedades del sistema nervioso central (snc) con estimulantes de guanilato ciclasa soluble (sgc).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022010852A MX2022010852A (es) 2016-11-08 2019-05-07 Tratamiento de enfermedades del sistema nervioso central (snc) con estimulantes de guanilato ciclasa soluble (sgc).

Country Status (17)

Country Link
US (2) US11690828B2 (es)
EP (1) EP3538096B1 (es)
JP (2) JP7150740B2 (es)
KR (1) KR102475124B1 (es)
CN (1) CN110267658B (es)
AU (2) AU2017359018C1 (es)
BR (1) BR112019009449A2 (es)
CA (1) CA3042548A1 (es)
CL (1) CL2019001256A1 (es)
EA (1) EA201991147A1 (es)
IL (1) IL266275B2 (es)
MA (1) MA46752A (es)
MX (2) MX2019005342A (es)
PH (1) PH12019501016A1 (es)
SG (1) SG10202104865UA (es)
TW (1) TWI812601B (es)
WO (1) WO2018089328A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019055859A1 (en) * 2017-09-14 2019-03-21 Ironwood Pharmaceuticals, Inc. TREATMENT OF METABOLIC SYNDROME BY SGC STIMULATOR
US20210177846A1 (en) 2018-07-11 2021-06-17 Cyclerion Therapeutics, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS
WO2021111419A1 (en) * 2019-12-05 2021-06-10 Cadila Healthcare Limited Modified release pharmaceutical compositions of riociguat
CN112924573B (zh) * 2021-01-21 2022-01-04 山东英盛生物技术有限公司 一种阿比多尔、利巴韦林、氯喹的hplc-ms/ms检测方法
WO2023130028A1 (en) * 2021-12-31 2023-07-06 Tenax Therapeutics, Inc. Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3995631A (en) 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US4203440A (en) 1978-10-23 1980-05-20 Alza Corporation Device having variable volume chamber for dispensing useful agent
US4627850A (en) 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
DE3660408D1 (en) 1985-02-27 1988-08-25 Oerlikon Buehrle Ag Apparatus for measuring the vibrations of a spiral bevel gear transmission in a gear-testing machine
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5324280A (en) 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
JP2928079B2 (ja) 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
CA2336807C (en) 1998-07-08 2010-04-13 Aventis Pharma Deutschland Gmbh Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them
DE19830430A1 (de) 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
PT1140012E (pt) 1998-12-17 2004-05-31 Alza Corp Conversao de capsulas de gelatina cheias com liquido em sistemas de libertacao controlada por camadas multiplas
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10216145A1 (de) 2002-04-12 2003-10-23 Bayer Ag Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
RU2006102981A (ru) 2003-08-04 2007-09-20 Пфайзер Продактс Инк. (Us) Лекарственные формы, обеспечивающие контролируемое высвобождение ингибиторов белка-переносчика эфиров холестерина и немедленное высвобождение ингибиторов hmg-соа-редуктазы
DE102006020327A1 (de) * 2006-04-27 2007-12-27 Bayer Healthcare Ag Heterocyclisch substituierte, anellierte Pyrazol-Derivate und ihre Verwendung
CA2698332C (en) 2007-09-06 2012-08-21 Merck Sharp & Dohme Corp. Pyrazole derivatives as soluble guanylate cyclase activators
EP2244575B1 (en) 2008-01-24 2013-07-17 Merck Sharp & Dohme Corp. Angiotensin ii receptor antagonists
EP2373317B1 (en) 2008-11-25 2016-12-14 Merck Sharp & Dohme Corp. 4-amino-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one or 4-amino-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one derivatives as activators of the soluble guanylat cyclase for the treatment of cardiovascular diseases
CN102414194A (zh) 2009-02-26 2012-04-11 默沙东公司 可溶性鸟苷酸环化酶激活剂
US9284301B2 (en) 2010-03-25 2016-03-15 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
US9365574B2 (en) 2010-05-27 2016-06-14 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
WO2012058132A1 (en) 2010-10-28 2012-05-03 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
CN108463224A (zh) * 2015-12-14 2018-08-28 铁木医药有限公司 sGC刺激剂用于胃肠功能障碍治疗的应用
WO2017108441A1 (en) 2015-12-22 2017-06-29 Universiteit Maastricht Treatment of cognitive impairment with cgc stimulator
WO2017121700A1 (de) 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft 1,3-disubstituierte 1h-pyrazolo[3,4-b]pyridin- derivate und ihre verwendung als stimulatoren der löslichen guanylatcyclase
CR20190101A (es) * 2016-09-02 2019-07-04 Ironwood Pharmaceuticals Inc Estimuladores de sgc

Also Published As

Publication number Publication date
AU2017359018B2 (en) 2023-08-31
TWI812601B (zh) 2023-08-21
WO2018089328A8 (en) 2019-03-28
US20230381153A1 (en) 2023-11-30
SG10202104865UA (en) 2021-06-29
MA46752A (fr) 2019-09-18
CL2019001256A1 (es) 2019-10-04
AU2023270267A1 (en) 2023-12-07
IL266275B2 (en) 2023-12-01
CN110267658A (zh) 2019-09-20
JP7150740B2 (ja) 2022-10-11
TW201822765A (zh) 2018-07-01
EP3538096A1 (en) 2019-09-18
EA201991147A1 (ru) 2019-11-29
US11690828B2 (en) 2023-07-04
AU2017359018C1 (en) 2023-12-21
IL266275A (en) 2019-06-30
US20190343813A1 (en) 2019-11-14
JP2019534327A (ja) 2019-11-28
KR102475124B1 (ko) 2022-12-08
CA3042548A1 (en) 2018-05-17
BR112019009449A2 (pt) 2019-07-30
JP2022160605A (ja) 2022-10-19
MX2022010852A (es) 2022-09-27
PH12019501016A1 (en) 2019-09-09
IL266275B1 (en) 2023-08-01
CN110267658B (zh) 2024-02-02
EP3538096C0 (en) 2024-02-28
EP3538096B1 (en) 2024-02-28
WO2018089328A1 (en) 2018-05-17
KR20190094167A (ko) 2019-08-12
AU2017359018A1 (en) 2019-05-30

Similar Documents

Publication Publication Date Title
PH12019500461A1 (en) Fused bicyclic sgc stimulators
PH12019501016A1 (en) Treatment of cns diseases with sgc stimulators
MX2022001565A (es) Formas solidas de un estimulador de guanilato ciclasa soluble (sgc).
PH12020550956A1 (en) Sgc stimulators
PH12019501017A1 (en) Sgc stimulators
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
MX2019012884A (es) Terapia de combinacion.
BR112018015718A2 (pt) utilização de estimuladores de sgc para o tratamento de esteato-hepatite não alcoólica (nash)
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
MX2016012799A (es) Metodos para tratar el virus de la hepatitis c.
MX2021013139A (es) Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.
MX2015012536A (es) Combinacion de agentes antivirales de accion directa y ribavirina para el tratamiento de pacientes con vhc.
MX2021002321A (es) Nuevos metodos.
PH12021550047A1 (en) USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS
MX2019011620A (es) Dosis y regimen para un inhibidor de la interaccion de hdm2-p53 en tumores hematologicos.
MX2021002322A (es) Nuevos metodos.
MX2018000240A (es) Metodos para tratar el vhc.
CR20230532A (es) ESTIMULADORES DE GUANILIL CICLASA SOLUBLE (sGC)
MX2016012722A (es) Metodos para tratar el virus de la hepatitis c.
WO2015102850A3 (en) Compositions, devices and methods for treating infections
WO2014140680A8 (en) Dosing regimen for use of celgosivir as an antiviral therapeutic for dengue virus infection
AR125221A2 (es) Estimuladores de sgc
MX2020001422A (es) Metodos para el tratamiento de hcv.
MX2018001905A (es) Metodos para el tratamiento del virus de hepatitis c (vhc).
UA115063U (xx) Спосіб лікування собак із больовим синдромом при панкреатиті